AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25733243 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐methyl‐l‐thiocitrulline (SMTC, 0.05, 0.1, and 0.2 μmol/min)
Number of subjects: 88
Study 25733243 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine
Number of subjects: 88
Study 25733243 — intervention group
Group type: COMPARATOR
Intervention: Control (normotensive subjects)
Number of subjects: 88
Study 25733243 — intervention group
Group type: COMPARATOR
Intervention: Control (hypertensive subjects)
Number of subjects: 88
Study 24455682 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptolide (1 mg/kg · d) combined with prednisone (2 mg/kg · d) for 6 to 9 months
Number of subjects: 56
Study 24455682 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 56
Study 21165798 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusion (OCC)
Number of subjects: 15
Study 21165798 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 15
Study 19055184 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 12
Study 19055184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16579250 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative physical training (muscular strength and work capacity)
Number of subjects: 0
Study 16579250 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (relaxation exercises, hot wrappings, and massage)
Number of subjects: 0
Study 16579250 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative physical training
Number of subjects: 0
Study 16579250 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 15101027 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined salbutamol and ipratropium bromide
Number of subjects: 22
Study 15101027 — intervention group
Group type: COMPARATOR
Intervention: Nebulized saline (placebo)
Number of subjects: 22
Study 10694120 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (CR) loading (20 g x d(‐1) for 5 days)
Number of subjects: 14
Study 9060898 — intervention group
Group type: EXPERIMENTAL
Intervention: 79% helium/21% oxygen mixture (He)
Number of subjects: 15
Study 9060898 — intervention group
Group type: COMPARATOR
Intervention: Room air (RA)
Number of subjects: 15
Study 8112803 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg zinc sulphate (elemental Zn 45 mg) orally/day
Number of subjects: 106
Study 8112803 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated group of 62)
Number of subjects: 106
Study 3533088 — intervention group
Group type: EXPERIMENTAL
Intervention: Spleen dialysate Solcosplen (2 ampoules i.m. t.i.d. for 1 week, followed by 2 dragees b.i.d. for 7 weeks)
Number of subjects: 40
Study 3533088 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study 2461017 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Logiparin) 35 XaI mu/kg b.w. once daily for 7 days
Number of subjects: 100
Study 2461017 — intervention group
Group type: COMPARATOR
Intervention: Dextran 70
Number of subjects: 100
Study 31564231 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.40 mg/kg tenecteplase (max 40 mg)
Number of subjects: 0
Study 31564231 — intervention group
Group type: COMPARATOR
Intervention: 0.25 mg/kg tenecteplase (max 25 mg)
Number of subjects: 0
Study 29174779 — intervention group
Group type: EXPERIMENTAL
Intervention: High external suction (‐20 cm H2O)
Number of subjects: 106
Study 29174779 — intervention group
Group type: COMPARATOR
Intervention: Low external suction (‐5 cm H2O)
Number of subjects: 106
Study 25740743 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil-rich meals
Number of subjects: 84
Study 25740743 — intervention group
Group type: COMPARATOR
Intervention: Conventional low-oil meals
Number of subjects: 84
Study 25740743 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study 23916618 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediolateral (ML) translations of the walking surface
Number of subjects: 19
Study 23916618 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait adaptability task
Number of subjects: 19
Study 21090875 — intervention group
Group type: EXPERIMENTAL
Intervention: ODD dimension of hurtfulness
Number of subjects: 177
Study 21090875 — intervention group
Group type: EXPERIMENTAL
Intervention: ODD dimension of irritability
Number of subjects: 177
Study 21090875 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment ADHD
Number of subjects: 177
Study 21090875 — intervention group
Group type: EXPERIMENTAL
Intervention: Callous-unemotional (CU) traits
Number of subjects: 177
Study 18438559 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% NaOCl
Number of subjects: 60
Study 18438559 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% NaOCl+17% EDTA
Number of subjects: 60
Study 18438559 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiphany
Number of subjects: 60
Study 18438559 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus
Number of subjects: 60
Study 18438559 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 60
Study 16989200 — intervention group
Group type: EXPERIMENTAL
Intervention: Local cutaneous alpha therapy with radon applicator (7.4 Bq/l, 90 minutes)
Number of subjects: 42
Study 16989200 — intervention group
Group type: COMPARATOR
Intervention: EHF (460 MHz) electromagnetic field
Number of subjects: 42
Study 15558381 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 20
Study 15558381 — intervention group
Group type: COMPARATOR
Intervention: Constraint-Induced Therapy (CIT)
Number of subjects: 20
Study 11401128 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET) three times a week for six months at 60% of peak VO2
Number of subjects: 118
Study 11401128 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET)
Number of subjects: 118
Study 11401128 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 118
Study 9029747 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole alone
Number of subjects: 24
Study 9029747 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole with dexamethasone
Number of subjects: 24
Study 9029747 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole with dexamethasone and cimetidine
Number of subjects: 24
Study 8117358 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 g sugar‐beet fibre/d
Number of subjects: 9
Study 3494725 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (2 g single dose)
Number of subjects: 280
Study 3494725 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimorazole (2 g single dose)
Number of subjects: 280
Study 3494725 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (2 g single dose)
Number of subjects: 280
Study 30197317 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced transrectal ultrasound (CETRUS)
Number of subjects: 207
Study 30197317 — intervention group
Group type: COMPARATOR
Intervention: Transrectal ultrasonography (TRUS)
Number of subjects: 207
Study 27635617 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantogam syrup 10% (hopantenic acid)
Number of subjects: 60
Study 27635617 — intervention group
Group type: COMPARATOR
Intervention: Psychological methods (Control group)
Number of subjects: 60
Study 25055492 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (Group C)
Number of subjects: 127
Study 25055492 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined general‐epidural anaesthesia (Group CA)
Number of subjects: 127
Study 25055492 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia with Droperidolum (Group D)
Number of subjects: 127
Study 22416791 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotora-taught cancer screening/prevention classes delivered individually (IND)
Number of subjects: 1006
Study 22416791 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotora-taught cancer screening/prevention classes delivered in social support groups (SSG)
Number of subjects: 1006
Study 20579955 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone administered in a randomized controlled trial of weekly antenatal corticosteroids (ACS)
Number of subjects: 100
Study 20579955 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonobese women)
Number of subjects: 100
Study 17943385 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) pneumoperitoneum (CO(2)PP)
Number of subjects: 20
Study 17943385 — intervention group
Group type: COMPARATOR
Intervention: Laparolift (abdominal wall elevator)
Number of subjects: 20
Study 15946117 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 15)
Number of subjects: 25
Study 15946117 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 25
Study 12889565 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous acetic acid injection (PAI) using 50% acetic acid
Number of subjects: 125
Study 12889565 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous ethanol injection (PEI) using pure ethanol
Number of subjects: 125
Study 10967901 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistive load (10 cmH2O/L/sec) during quiet breathing
Number of subjects: 23
Study 10967901 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistive load during hypercapnic stimulation
Number of subjects: 23
Study 10967901 — intervention group
Group type: COMPARATOR
Intervention: Inspiratory resistive load during loaded breathing
Number of subjects: 23
Study 10967901 — intervention group
Group type: COMPARATOR
Intervention: Inspiratory resistive load during hypoxic stimulation
Number of subjects: 23
Study 9234616 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with ciprofloxacin (CPFX) and clarithromycin (CAM), 600 mg/day for 14 days
Number of subjects: 0
Study 9234616 — intervention group
Group type: COMPARATOR
Intervention: Single therapy with ciprofloxacin (CPFX), 600 mg/day for 14 days
Number of subjects: 0
Study 7690225 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% sodium chloride (hypertonic saline)
Number of subjects: 0
Study 7690225 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 0
Study 7690225 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% sodium chloride combined with 6% dextran 70
Number of subjects: 0
Study 7690225 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% sodium chloride combined with 12% dextran 70
Number of subjects: 0
Study 2871742 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 144
Study 2871742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 31127779 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) targeting the right dorsolateral prefrontal cortex, 10 sessions
Number of subjects: 21
Study 31127779 — intervention group
Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 21
Study 28007405 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 50 mg daily in 2 doses
Number of subjects: 4
Study 28007405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 25999694 — intervention group
Group type: EXPERIMENTAL
Intervention: SYP‐1018 (200 mg)
Number of subjects: 52
Study 25999694 — intervention group
Group type: COMPARATOR
Intervention: Vfend(®) (200 mg)
Number of subjects: 52
Study 25999694 — intervention group
Group type: EXPERIMENTAL
Intervention: SYP‐1018 and Vfend(®)
Number of subjects: 52
Study 23758690 — intervention group
Group type: EXPERIMENTAL
Intervention: Specially developed training programme
Number of subjects: 40
Study 23758690 — intervention group
Group type: COMPARATOR
Intervention: Usual methods of implementation and training
Number of subjects: 40
Study 22038637 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic IABP insertion (group B, n=52)
Number of subjects: 104
Study 22038637 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic IABP insertion (group A, n=52)
Number of subjects: 104
Study 22038637 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic IABP insertion (group B)
Number of subjects: 104
Study 22038637 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic IABP insertion (group A)
Number of subjects: 104
Study 19508963 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular aiming strategy
Number of subjects: 2
Study 19508963 — intervention group
Group type: EXPERIMENTAL
Intervention: Different control strategy applied by experts
Number of subjects: 2
Study 19508963 — intervention group
Group type: COMPARATOR
Intervention: Novice aiming strategy
Number of subjects: 2
Study 17131250 — intervention group
Group type: EXPERIMENTAL
Intervention: Proview self-tonometer
Number of subjects: 150
Study 17131250 — intervention group
Group type: COMPARATOR
Intervention: Goldmann applanation tonometry (GAT)
Number of subjects: 150
Study 15527607 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises and manometric biofeedback
Number of subjects: 55
Study 15527607 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle changes (control group)
Number of subjects: 55
Study 15527607 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 55
Study 11419612 — intervention group
Group type: EXPERIMENTAL
Intervention: High responsibility condition
Number of subjects: 0
Study 11419612 — intervention group
Group type: EXPERIMENTAL
Intervention: Low responsibility condition
Number of subjects: 0
Study 11419612 — intervention group
Group type: COMPARATOR
Intervention: No responsibility condition
Number of subjects: 0
Study 11419612 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsibility manipulation
Number of subjects: 0
Study 9576319 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal adjustment
Number of subjects: 146
Study 9576319 — intervention group
Group type: COMPARATOR
Intervention: Mock adjustment
Number of subjects: 146
Study 7935028 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose hormone replacement (0.3 mg/day equine estrogen and 2.5 mg/day medroxyprogesterone)
Number of subjects: 75
Study 7935028 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose hormone replacement (0.625 mg/day equine estrogen, days 1‐25, and 5 mg/day medroxyprogesterone, days 16‐25)
Number of subjects: 75
Study 7935028 — intervention group
Group type: COMPARATOR
Intervention: Calcium only (control group)
Number of subjects: 75
Study 3284690 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (prazosin 2 mg b.i.d. and verapamil 160 mg b.i.d.)
Number of subjects: 12
Study 3284690 — intervention group
Group type: EXPERIMENTAL
Intervention: Single drug treatment (prazosin or verapamil)
Number of subjects: 12
Study 3284690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29611086 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (RSV) 1g daily for 3 months with conventional treatment
Number of subjects: 100
Study 29611086 — intervention group
Group type: COMPARATOR
Intervention: Control group with regular treatment only
Number of subjects: 100
Study 28214091 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation
Number of subjects: 85
Study 28214091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 25204719 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark roast coffee (rich in N‐methylpyridinium)
Number of subjects: 118
Study 25204719 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium roast coffee (rich in caffeoylquinic acids, trigonelline)
Number of subjects: 118
Study 25204719 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 118
Study 23425539 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI with bivalirudin
Number of subjects: 3602
Study 21934625 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg per day
Number of subjects: 33
Study 21934625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 19784722 — intervention group
Group type: EXPERIMENTAL
Intervention: Karayahesive hydrocolloid dressing
Number of subjects: 253
Study 19784722 — intervention group
Group type: COMPARATOR
Intervention: Tegaderm plus Pad polyurethane foam dressing
Number of subjects: 253
Study 17010231 — intervention group
Group type: COMPARATOR
Intervention: Diet C (increased consumption of breakfast cereals)
Number of subjects: 67
Study 17010231 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet V (increased consumption of vegetables)
Number of subjects: 67
Study 17010231 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 67
Study 15592786 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% bromfenac sodium (Bromfenac)
Number of subjects: 22
Study 15592786 — intervention group
Group type: COMPARATOR
Intervention: 0.1% pemirolast potassium (Pemirolast)
Number of subjects: 22
Study 11122840 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard and high-dose chemotherapy
Number of subjects: 0
Study 9132724 — intervention group
Group type: EXPERIMENTAL
Intervention: Random practice schedule
Number of subjects: 19
Study 9132724 — intervention group
Group type: COMPARATOR
Intervention: Blocked practice schedule
Number of subjects: 19
Study 7617628 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactivin
Number of subjects: 49
Study 7617628 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemotherapy (Tactivin + antibacterial drugs)
Number of subjects: 49
Study 7617628 — intervention group
Group type: COMPARATOR
Intervention: Antibacterial drugs alone (Control)
Number of subjects: 49
Study 2929485 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal protein (AP) diet with increasing vitamin B‐6 intake (0.5, 1.0, 1.5, and 2.0 mg/d) for 14‐21 d
Number of subjects: 8
Study 2929485 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant protein (PP) diet with increasing vitamin B‐6 intake (0.5, 1.0, 1.5, and 2.0 mg/d) for 14‐21 d
Number of subjects: 8
Study 2929485 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal protein (AP) diet
Number of subjects: 8
Study 2929485 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant protein (PP) diet
Number of subjects: 8
Study 323074 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest dose of norgestrel-ethinyl estradiol (20 microng estrogen, 100 microng progestogen)
Number of subjects: 0
Study 323074 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of norgestrel-ethinyl estradiol (20 microng estrogen, increased progestogen in 100-microng increments)
Number of subjects: 0
Study 323074 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of norgestrel-ethinyl estradiol
Number of subjects: 0
Study 31047803 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan at recommended doses for expansion (5.4 mg/kg or 6.4 mg/kg) administered intravenously once every 3 weeks.
Number of subjects: 115
Study 31047803 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan at recommended doses for expansion (5.4 mg/kg or 6.4 mg/kg).
Number of subjects: 115
Study 27364549 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 5mg
Number of subjects: 127
Study 27364549 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 10mg (dose-escalation)
Number of subjects: 127
Study 27364549 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 20mg (dose-escalation)
Number of subjects: 127
Study 27364549 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 5mg, 10mg, 20mg
Number of subjects: 127
Study 25118042 — intervention group
Group type: EXPERIMENTAL
Intervention: FOX computer‐assisted fitting
Number of subjects: 27
Study 25118042 — intervention group
Group type: COMPARATOR
Intervention: Conventional programming methods
Number of subjects: 27
Study 25176085 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 40
Study 25176085 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 40
Study 25176085 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 21700688 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic mountain sickness (CMS) patients
Number of subjects: 23
Study 21700688 — intervention group
Group type: COMPARATOR
Intervention: Healthy mountain dwellers (control group)
Number of subjects: 23
Study 21700688 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen inhalation in CMS patients
Number of subjects: 23
Study 21700688 — intervention group
Group type: COMPARATOR
Intervention: Oxygen inhalation in hypoxemic control subjects
Number of subjects: 23
Study 21700688 — intervention group
Group type: COMPARATOR
Intervention: Oxygen inhalation in normoxemic control subjects
Number of subjects: 23
Study 21058471 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy group (acupuncture and mild moxibustion)
Number of subjects: 60
Study 21058471 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture group
Number of subjects: 60
Study 17936534 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine and 3-hydroxydesloratadine concentrations measured using LC/MS/MS method
Number of subjects: 0
Study 16338255 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg loading dose, then 75 mg/d) in addition to aspirin for up to 1 year
Number of subjects: 12562
Study 16338255 — intervention group
Group type: COMPARATOR
Intervention: Placebo in addition to aspirin for up to 1 year
Number of subjects: 12562
Study 11888520 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (30 g for 1 h)
Number of subjects: 17
Study 11888520 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 17
Study 11888520 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy men)
Number of subjects: 17
Study 9489273 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated imaginal reliving of trauma during exposure therapy
Number of subjects: 37
Study 9489273 — intervention group
Group type: EXPERIMENTAL
Intervention: High initial engagement without habituation
Number of subjects: 37
Study 9489273 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate initial engagement without habituation
Number of subjects: 37
Study 8919895 — intervention group
Group type: EXPERIMENTAL
Intervention: PCINA (0.025 mg fentanyl over 6 min)
Number of subjects: 75
Study 8919895 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v.‐PCA (0.025 mg fentanyl bolus, lockout interval 6 min)
Number of subjects: 75